Australasian Biotechnology,
Volume 8 Number 2, March/April 1998, pp. 77-80
CONFERENCE PAPER
Biopartnering - An illustration
Mitzi Gilligan, Minter Ellison
Code Number:AU98014
Sizes of Files:
Text: 17K
Graphics: No associated
graphics files
The aim of this article is to provide a general outline of
some of the commercial and legal issues
which must be considered when negotiating a biopartnering deal. I
have chosen to focus on a
biopartnering deal between a biotechnology company and a larger
(and possibly international)
pharmaceutical company. The article therefore mainly considers
the issues surrounding
biopartnering in human therapeutics where both parties are
corporate entities. Whilst some
different factors will apply in relation to other types of
biopartnering, for example, where one of
the parties is an academic or charitable research organisation,
or the field is not human
therapeutics, many of the general issues will remain the same. In
order to make this article more
digestible, I have chosen the format of an imaginary letter to me
by a fictional client which I call
"Cureall Biotech". The letter requests some advice on a proposed
biopartnering deal and my
response outlines the issues to be considered.
Copyright 1998 Australian Biotechnology Association Ltd.
